MARKET

BFRI

BFRI

Biofrontera Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

1.900
-0.050
-2.56%
Closed 19:56 06/28 EDT
OPEN
1.970
PREV CLOSE
1.950
HIGH
1.990
LOW
1.810
VOLUME
483.03K
TURNOVER
--
52 WEEK HIGH
14.63
52 WEEK LOW
1.810
MARKET CAP
36.01M
P/E (TTM)
-0.5546
1D
5D
1M
3M
1Y
5Y
Biofrontera, Inc. Recognized for Rapid Sales Growth, Innovative Therapies and Marketing Excellence
Named Among the 10 Fastest-Growing Life Sciences Companies to Watch in 2022 by CIOCoverage Magazine New Ameluz® Marketing Campaign Receives Gold 2022 Award of Excellence from The Communicator Awards WOBURN, Mass, June 09, 2022 (GLOBE NEWSWIRE) -- Biofronte...
GlobeNewswire · 06/09 13:44
BRIEF-Biofrontera Inc Files Prospectus Relates To Offering And Resale From Time To Time By Selling Stockholder Of Up To 9.7 Million Shares Of Common Stock
reuters.com · 06/07 21:46
Biofrontera Inc. to Participate in The Benchmark Healthcare House Call Virtual 1x1 Conference
WOBURN, Mass., May 31, 2022 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, announced today that the Company will be participating in The Benchmark Healthcar...
GlobeNewswire · 05/31 14:42
Biofrontera Highlights Data From American Cancer Society As It Applies To Co.'s Ameluz Drug; BZ NOTE: This Type Of News Item Does Not Frequently Move Stocks
Biofrontera Inc. (NASDAQ:BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, views new data on skin cancer prevalence provided by the American Cancer Society1, indicating
Benzinga · 05/24 15:32
New Data and Forecasts for the U.S. Skin Cancer Market Strongly Support the Commercial Opportunity for Biofrontera’s Ameluz®
WOBURN, Mass., May 24, 2022 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, views new data on skin cancer prevalence provided by the American Cancer Society1...
GlobeNewswire · 05/24 15:29
Biofrontera Inc. Announces Closing of $9.4 Million Private Placement
WOBURN, Mass., May 19, 2022 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, announced today the closing of its previously-announced $9.4 million private plac...
GlobeNewswire · 05/19 13:48
BRIEF-Biofrontera Inc Announces Pricing Of $9.4 Million Private Placement
reuters.com · 05/16 12:18
Biofrontera Prices ~3.4M Share Offering Of Common Stock, Warrant At $2.75/Unit
Biofrontera, Inc. (NASDAQ:BFRI, BFRIW)), announced today that it has entered into a securities purchase agreement with a single institutional investor for the purchase of 3,419,000 shares of its common stock (or common
Benzinga · 05/16 12:14
More
No Data
Learn about the latest financial forecast of BFRI. Analyze the recent business situations of Biofrontera Inc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 2 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

0.00%Strong Buy
100.00%Buy
0.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average BFRI stock price target is 15.50 with a high estimate of 20.00 and a low estimate of 11.00.
High20.00
Average15.50
Low11.00
Current 1.820
EPS
Actual
Estimate
-1.60-1.20-0.80-0.40
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Institutional Holdings
Institutions: 12
Institutional Holdings: 798.54K
% Owned: 4.21%
Shares Outstanding: 18.95M
TypeInstitutionsShares
Increased
4
147.45K
New
5
170.84K
Decreased
2
99.06K
Sold Out
7
121.20K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
+0.61%
Pharmaceuticals & Medical Research
+0.49%
Key Executives
Chairman/Executive Director
Hermann Lubbert
Chief Executive Officer
Erica Monaco
Director
John Borer
Director
Kevin Weber
Independent Director
Beth Hoffman
Independent Director
Loretta Wedge
No Data
No Data
About BFRI
Biofrontera Inc. is a biopharmaceutical company. The Company is specialized in the commercialization of pharmaceutical products for the treatment of dermatological conditions for the diseases caused primarily by exposure to sunlight that result in sun damage to the skin. Its products focus on the treatment of actinic keratoses, which are skin lesions that lead to skin cancer. It also markets a topical antibiotic for treatment of impetigo, a bacterial skin infection. The Company’s principal product is Ameluz, which is a prescription drug for use in combination with its medical device, the BF-RhodoLED lamp, for photodynamic therapy (PDT) in the United States for the lesion-directed and field-directed treatment of actinic keratosis of mild-to-moderate severity on the face and scalp. It offers Xepi for the treatment of impetigo, a common skin infection, due to Staphylococcus aureus or streptococcus pyogenes.

Webull offers kinds of Biofrontera Inc stock information, including NASDAQ:BFRI real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, BFRI stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading BFRI stock methods without spending real money on the virtual paper trading platform.